Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1999 1
2000 1
2001 1
2002 1
2004 3
2005 1
2008 2
2009 2
2010 1
2011 2
2012 4
2013 5
2014 1
2015 1
2016 2
2017 2
2018 2
2019 2
2020 4
2021 2
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Platinum-Resistant Fallopian Tube Carcinoma"
Page 1
The Many Microenvironments of Ovarian Cancer.
Micek HM, Visetsouk MR, Fleszar AJ, Kreeger PK. Micek HM, et al. Adv Exp Med Biol. 2020;1296:199-213. doi: 10.1007/978-3-030-59038-3_12. Adv Exp Med Biol. 2020. PMID: 34185294 Free PMC article. Review.
While this knowledge may provide valuable insight into better prognosis and treatments for HGSOCs, its collection, synthesis, and application are complicated by the number of unique microenvironments in the disease-the initiating site (fallopian tube), first …
While this knowledge may provide valuable insight into better prognosis and treatments for HGSOCs, its collection, synthesis, and app …
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
Nwabufo CK. Nwabufo CK. Cancer Chemother Pharmacol. 2024 Feb;93(2):89-105. doi: 10.1007/s00280-023-04575-y. Epub 2023 Aug 18. Cancer Chemother Pharmacol. 2024. PMID: 37594572 Review.
Mirvetuximab soravtansine was granted accelerated approval by the US FDA on November 14, 2022, for the treatment of adult patients with FRalpha positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have receiv …
Mirvetuximab soravtansine was granted accelerated approval by the US FDA on November 14, 2022, for the treatment of adult patients with FRal …
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
Tatsuki S, Shoji T, Abe M, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Aida T, Baba T. Tatsuki S, et al. Anticancer Res. 2022 Sep;42(9):4603-4610. doi: 10.21873/anticanres.15964. Anticancer Res. 2022. PMID: 36039449
BACKGROUND/AIM: Ovarian cancer diagnosed with platinum-resistant recurrence has very poor prognosis and single-agent chemotherapy with no cross-resistance to prior chemotherapy is recommended for its treatment. ...PATIENTS AND METHODS: The study included 49 p …
BACKGROUND/AIM: Ovarian cancer diagnosed with platinum-resistant recurrence has very poor prognosis and single-agent ch …
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S, Giannone G, Clamp AR, Ennis DP, Glasspool RM, Herbertson R, Krell J, Riisnaes R, Mirza HB, Cheng Z, McDermott J, Green C, Kristeleit RS, George A, Gourley C, Lewsley LA, Rai D, Banerji U, Hinsley S, McNeish IA. Banerjee S, et al. JAMA Oncol. 2023 May 1;9(5):675-682. doi: 10.1001/jamaoncol.2022.7966. JAMA Oncol. 2023. PMID: 36928279 Free PMC article. Clinical Trial.
IMPORTANCE: Patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-HGSC) have a poor prognosis and few therapeutic options. ...DESIGN, SETTING, AND PARTICIPANTS: This phase 2, double-blind, placebo-controlled multicenter …
IMPORTANCE: Patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-HGSC) have a poor …
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
Liao JB, Gwin WR, Urban RR, Hitchcock-Bernhardt KM, Coveler AL, Higgins DM, Childs JS, Shakalia HN, Swensen RE, Stanton SE, Tinker AV, Wahl TA, Ancheta RG, McGonigle KF, Dai JY, Disis ML, Goff BA. Liao JB, et al. J Immunother Cancer. 2021 Sep;9(9):e003122. doi: 10.1136/jitc-2021-003122. J Immunother Cancer. 2021. PMID: 34531249 Free PMC article.
We assessed activity and safety of pembrolizumab with carboplatin in recurrent platinum-resistant ovarian cancer. PATIENTS AND METHODS: This phase I/II, single-arm clinical trial studied concurrent carboplatin and pembrolizumab in recurrent platinum-resist …
We assessed activity and safety of pembrolizumab with carboplatin in recurrent platinum-resistant ovarian cancer. PATIENTS AND …
Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer.
Kobayashi-Kato M, Yunokawa M, Bun S, Miyasaka N, Kato T, Tamura K. Kobayashi-Kato M, et al. Cancer Chemother Pharmacol. 2019 Jul;84(1):33-39. doi: 10.1007/s00280-019-03834-1. Epub 2019 Apr 13. Cancer Chemother Pharmacol. 2019. PMID: 30982097
BACKGROUND/OBJECTIVE: Platinum-refractory or -resistant ovarian cancer (PRROC) is associated with poor prognosis and low response to further chemotherapy. We investigated predictors of effectiveness of following treatments for PRROC. PATIENTS AND METHODS: We include …
BACKGROUND/OBJECTIVE: Platinum-refractory or -resistant ovarian cancer (PRROC) is associated with poor prognosis and low response to …
Randomised phase II trial of weekly ixabepilone biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Roque DM, et al. Br J Cancer. 2022 Jun;126(12):1695-1703. doi: 10.1038/s41416-022-01717-6. Epub 2022 Feb 11. Br J Cancer. 2022. PMID: 35149854 Free PMC article. Clinical Trial.
BACKGROUND: This multi-center RP2 study assessed activity/safety of ixabepilone + bevacizumab compared to ixabepilone in platinum-resistant/refractory ovarian/fallopian tube/primary peritoneal cancer. ...Prior receipt of BEV should not preclude the use …
BACKGROUND: This multi-center RP2 study assessed activity/safety of ixabepilone + bevacizumab compared to ixabepilone in platinum- …
Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer.
Hamontri S, Tantitamit T. Hamontri S, et al. Asian Pac J Cancer Prev. 2023 Apr 1;24(4):1401-1405. doi: 10.31557/APJCP.2023.24.4.1401. Asian Pac J Cancer Prev. 2023. PMID: 37116164 Free PMC article.
METHODS: Women with recurrent platinum-resistant and refractory EOC, tubal and peritoneal cancer who received treatment at the HRH Princess Maha Chakri Sirindhorn Medical Center (MSMC) between January 2010 and December 2019 were included. ...Kaplan-Meier was used to …
METHODS: Women with recurrent platinum-resistant and refractory EOC, tubal and peritoneal cancer who received treatment at the …
Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C, Charakorn C, Chittithaworn S, Lertkhachonsuk AA. Kongsawatvorakul C, et al. J Obstet Gynaecol. 2022 Aug;42(6):2331-2335. doi: 10.1080/01443615.2022.2049724. Epub 2022 Apr 26. J Obstet Gynaecol. 2022. PMID: 35470751
The aim of treatment in recurrent or refractory epithelial ovarian cancer is palliation. In a patient with platinum-resistant status, several chemotherapy regimens have been reported with similar response rates. ...After the recurrence of epithelial ovarian cancer, …
The aim of treatment in recurrent or refractory epithelial ovarian cancer is palliation. In a patient with platinum-resistant …
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Musacchio L, Salutari V, Pignata S, Braicu E, Cibula D, Colombo N, Frenel JS, Zagouri F, Carbone V, Ghizzoni V, Giolitto S, Giudice E, Perri MT, Ricci C, Scambia G, Lorusso D. Musacchio L, et al. Int J Gynecol Cancer. 2021 Oct;31(10):1369-1373. doi: 10.1136/ijgc-2021-002593. Int J Gynecol Cancer. 2021. PMID: 34607820 Clinical Trial.
BACKGROUND: Platinum-resistant ovarian cancer patients have a poor prognosis and few treatment options are available. ...
BACKGROUND: Platinum-resistant ovarian cancer patients have a poor prognosis and few treatment options are available. . …
45 results